DOI: 10.1055/s-00000077

Seminars in Thrombosis and Hemostasis

Issue 03 · Volume 43 · April 2017 DOI: 10.1055/s-007-33727 Laboratory Assessment of Hemostatic and Anticoagulant Therapy Guest Editors: Robert C. Gosselin, CLS, and Dorothy M. Adcock, MD.

Editorial

  • 235
    Favaloro, Emmanuel J.:

    2016 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

    • Preface

  • 242
    Adcock, Dorothy M.; Gosselin, Robert C.:

    Laboratory Assessment of Hemostatic and Anticoagulant Therapy

    • Original Article

  • 245
    Moffat, Karen A.; Lewis, Clinton W.:

    Laboratory Monitoring of Oral Vitamin K Anticoagulation

    • Review Article

  • 253
    Marlar, Richard A.; Clement, Bernadette; Gausman, Jana:

    Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations

  • 261
    Babin, Jennifer L.; Traylor, Katie L.; Witt, Daniel M.:

    Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux

  • 270
    Van Cott, Elizabeth M.; Roberts, A. Joshua; Dager, William E.:

    Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors

  • 277
    Douxfils, Jonathan; Gosselin, Robert C.:

    Laboratory Assessment of Direct Oral Anticoagulants

  • 291
    Winkler, Anne M.:

    Managing the Precarious Hemostatic Balance during Extracorporeal Life Support: Implications for Coagulation Laboratories

  • 300
    Kluft, Cornelis; Sidelmann, Johannes J.; Gram, Jørgen B.:

    Assessing Safety of Thrombolytic Therapy

  • 311
    Orme, Rachel; Judge, Heather M.; Storey, Robert F.:

    Monitoring Antiplatelet Therapy

  • 320
    Castellone, Donna D.; Adcock, Dorothy M.:

    Factor VIII Activity and Inhibitor Assays in the Diagnosis and Treatment of Hemophilia A

  • 331
    Kitchen, Steve; Tiefenbacher, Stefan; Gosselin, Robert:

    Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies

  • 338
    Favaloro, Emmanuel J.; Pasalic, Leonardo; Curnow, Jennifer:

    Monitoring Therapy during Treatment of von Willebrand Disease

    • Letter to the Editor

  • 355
    Kubisz, Peter; Stasko, Jan; Holly, Pavol:

    Use of Low-Dose Recombinant Activated Factor VII in the Off-Label Setting: A Comment to “The Judicious Use of Recombinant Factor VIIa”